Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial Studying the Efficacy of a Triplet Combination of MLN9708, Lenalidomide and Dexamethasone as Induction Prior to, and as Consolidation After High-dose Therapy With Peripheral Stem Cell Transplantation Followed by MLN9708 Maintenance in the Initial Management of Multiple Myeloma in Patients Younger Than 66 Years

NCT01936532 is registered in ClinicalTrials.gov with Nantes University Hospital as lead sponsor.

NCT NCT01936532
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01936532 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial Studying the Efficacy of a Triplet Combination of MLN9708, Lenalidomide and Dexamethasone as Induction Prior to, and as Consolidation After High-dose Therapy With Peripheral Stem Cell Transplantation Followed by MLN9708 Maintenance in the Initial Management of Multiple Myeloma in Patients Younger Than 66 Years
Lead sponsor
Nantes University Hospital
Phase
Phase 2
Overall status
Completed
Start date
November 12, 2014
Completion date
June 4, 2020
Enrollment
42 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

newly diagnosed multiple myeloma